In a patient with HbA1c approximately 15%, should I prescribe 4 units of premixed 70/30 insulin in the evening together with dapagliflozin 10 mg once daily and gliclazide 60 mg twice daily?

No, this regimen is inappropriate and potentially dangerous for a patient with HbA1c 15%

For severe hyperglycemia (HbA1c ≥10%), immediate basal-bolus insulin therapy is required, not a single evening dose of premixed insulin combined with oral agents. 1, 2 Your proposed regimen of 4 units 70/30 insulin in the evening plus dapagliflozin and gliclazide is fundamentally inadequate and contradicts evidence-based guidelines.

---

Critical Problems with Your Proposed Regimen

1. Premixed 70/30 Insulin Is Contraindicated

• Premixed insulin formulations are explicitly not recommended for hospital or outpatient use in patients requiring intensive glycemic control because randomized trials demonstrate a 64% hypoglycemia rate versus 24% with basal-bolus therapy, leading to early trial termination. 1, 3
• The fixed 70:30 ratio cannot be adjusted independently to match variable carbohydrate intake and activity patterns, increasing hypoglycemia risk when meal intake varies. 3
• A single evening dose of 4 units provides grossly inadequate insulin coverage for HbA1c 15%, which typically requires 0.3–0.5 units/kg/day as total daily insulin (approximately 21–35 units/day for a 70 kg patient). 1, 4, 2

2. Gliclazide Adds Unacceptable Hypoglycemia Risk

• Combining gliclazide with insulin markedly increases severe hypoglycemia risk and should be avoided. 1, 2
• Sulfonylureas are explicitly condemned when implementing basal-bolus insulin regimens because the combination significantly increases hypoglycemia without improving outcomes. 2, 3
• Sulfonylureas rank as the fourth leading cause of emergency-room admissions for drug-related side effects in adults >65 years. 3

3. Dapagliflozin Alone Cannot Achieve Target Control

• While dapagliflozin provides meaningful HbA1c reduction (approximately 0.6–0.8%), this is insufficient when starting from HbA1c 15%. 5, 6, 7
• SGLT2 inhibitors should be avoided during severe illness, in patients with ketonemia or ketonuria, and during prolonged fasting. 1
• The FDA warns that SGLT2 inhibitors should be stopped 3 days before scheduled surgeries (4 days for ertugliflozin). 1

---

Evidence-Based Regimen for HbA1c 15%

Immediate Basal-Bolus Insulin Therapy

Total Daily Insulin Dose Calculation:

• Start with 0.3–0.5 units/kg/day as total daily insulin for severe hyperglycemia (HbA1c ≥10%). 1, 4, 2
• For a 70 kg patient: 21–35 units/day total
• Split 50% as basal insulin (glargine, detemir, or degludec) once daily at bedtime: ≈11–18 units
• Split 50% as prandial insulin (lispro, aspart, or glulisine) divided across three meals: ≈4–6 units per meal 1, 4, 2

Basal Insulin Titration:

• Increase by 4 units every 3 days if fasting glucose ≥180 mg/dL 1, 4
• Increase by 2 units every 3 days if fasting glucose 140–179 mg/dL 1, 4
• Target fasting glucose: 80–130 mg/dL 1, 4

Prandial Insulin Titration:

• Adjust each meal dose by 1–2 units (10–15%) every 3 days based on 2-hour postprandial glucose 1, 4
• Target postprandial glucose: <180 mg/dL 1, 4

Correction Insulin Protocol:

• Add 2 units rapid-acting insulin for pre-meal glucose >250 mg/dL 1, 4
• Add 4 units for glucose >350 mg/dL 1, 4

---

Foundation Therapy: Metformin

• Continue or initiate metformin at maximum tolerated dose (up to 2000–2550 mg daily) unless contraindicated. 1, 4, 2
• Metformin reduces total insulin requirements by 20–30% and provides cardiovascular mortality benefit. 4, 2, 3
• Metformin must never be discontinued when insulin is added unless specifically contraindicated (eGFR <30 mL/min/1.73 m²). 4, 2, 3

---

Role of Dapagliflozin

• Continue dapagliflozin 10 mg daily for cardiovascular and renal protection, which is independent of glucose-lowering effect. 1, 3
• When added to insulin therapy, dapagliflozin provides additional HbA1c reduction of 0.6–0.8% and promotes weight loss of 2–5 kg. 5, 6, 7
• In real-world studies, dapagliflozin added to insulin reduced HbA1c by 1.0% at 6 months and decreased daily insulin requirements by 12 units. 6
• Monitor for euglycemic diabetic ketoacidosis: educate patients to stop dapagliflozin and seek urgent care if they develop dyspnea, nausea, vomiting, or abdominal pain. 3

---

Discontinue Gliclazide Immediately

• Stop gliclazide before or at the time insulin is started to avoid severe hypoglycemia. 2, 3
• Continuing sulfonylureas with basal-bolus insulin markedly raises hypoglycemia risk and should be avoided. 2, 3

---

Monitoring Requirements

• Daily fasting glucose during titration to guide basal insulin adjustments 1, 4
• Pre-meal glucose before each meal to calculate correction doses 1, 4
• 2-hour postprandial glucose to assess prandial insulin adequacy 1, 4
• HbA1c every 3 months until target achieved, then every 6 months 2, 3
• Renal function (eGFR) at baseline and annually for metformin safety 3
• Vitamin B12 levels periodically on long-term metformin, especially if anemia or neuropathy develops 3

---

Expected Clinical Outcomes

• With properly implemented basal-bolus therapy, ≈68% of patients achieve mean glucose <140 mg/dL versus ≈38% with sliding-scale insulin alone. 1, 4
• HbA1c reduction of 3–4% (from ~15% to 11–12%) is achievable within 3–6 months with intensive insulin titration. 4, 2
• No increase in hypoglycemia incidence when basal-bolus regimens are correctly implemented versus inadequate sliding-scale approaches. 1, 4
• Adding dapagliflozin to insulin provides additional 1.0% HbA1c reduction and 2–5 kg weight loss without increasing hypoglycemia risk. 5, 6, 7

---

Critical Pitfalls to Avoid

• Never use premixed insulin (70/30) in patients requiring intensive glycemic control due to unacceptably high hypoglycemia rates. 1, 3
• Never combine sulfonylureas with basal-bolus insulin as this markedly increases severe hypoglycemia risk. 2, 3
• Do not delay insulin intensification waiting for oral agents to work—at HbA1c 15%, only combination therapy with adequate insulin can reduce HbA1c to target. 2, 3
• Do not rely on 4 units of insulin for HbA1c 15%—this represents profound under-dosing and therapeutic failure. 1, 4, 2
• Do not discontinue metformin when starting insulin unless contraindicated—it remains foundational therapy throughout intensification. 4, 2, 3
• Do not use sliding-scale insulin as monotherapy—major diabetes guidelines condemn this approach as ineffective and dangerous. 1, 4

---

Summary Algorithm

For HbA1c 15%:

1. Discontinue gliclazide immediately 2, 3
2. Start basal-bolus insulin:
   • Basal: 11–18 units glargine once daily at bedtime 1, 4
   • Prandial: 4–6 units rapid-acting insulin before each meal 1, 4
3. Continue or start metformin 2000 mg daily (1000 mg BID) 4, 2, 3
4. Continue dapagliflozin 10 mg daily for cardiovascular/renal protection 3, 5, 6
5. Titrate insulin aggressively every 3 days until targets achieved 1, 4
6. Monitor daily fasting and pre-meal glucose 1, 4
7. Reassess HbA1c in 3 months; expect reduction to 11–12% 4, 2

This evidence-based approach provides the only pathway to achieving glycemic control in severe hyperglycemia while minimizing hypoglycemia risk and maximizing cardiovascular protection.